Outcome predictors in patients with hepatocellular carcinoma (HCC) who are treated with percutaneous ablation are ill defined, and it is unknown if successful therapy is associated with improved survival.
Dr Bruix and colleagues from Barcelona in Spain undertook a study on 282 cirrhotic patients with early nonsurgical HCC.
The participants were treated with percutaneous ablation during a 15-year period.
The researchers found single tumors in 244 patients, and 2 to 3 nodules were seen in 38 patients.
|Initial complete response to percutaneous ablation is associated with improved survival in Child-Turcotte-Pugh class A and B patients with|
The researchers noted initial complete response in 192 patients and it was independently related to the size of the main tumor and tumor stage (2 cm, 96%; 2.1-3 cm, 78%; >3 cm, 56%; 2-3 nodules, 46%).
At the end of follow-up, the research team recorded that 80 patients presented with a sustained complete response.
The 1-, 3-, and 5-year survival rates were 87%, 51%, and 27%, respectively.
The researchers found that the independent predictors of survival were Child-Turcotte-Pugh class and initial complete response.
Child-Turcotte-Pugh class A patients with initial complete response achieved 42% survival at 5 years; this figure increased to 63% in patients with tumors 2 cm or smaller.
Dr Bruix concluded, "Our results demonstrate that initial complete response to percutaneous ablation is associated with an improved survival in both Child-Turcotte-Pugh class A and B patients with nonsurgical HCC."
"Accordingly, initial complete tumor necrosis should be considered a relevant therapeutic target irrespective of tumor size and liver function."